These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16054143)

  • 1. A new assay for the discovery of Bcl-XL inhibitors.
    Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L
    Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
    Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
    J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
    Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
    J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms.
    Qian J; Voorbach MJ; Huth JR; Coen ML; Zhang H; Ng SC; Comess KM; Petros AM; Rosenberg SH; Warrior U; Burns DJ
    Anal Biochem; 2004 May; 328(2):131-8. PubMed ID: 15113688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening.
    Mukherjee P; Desai P; Zhou YD; Avery M
    J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A conserved hydrophobic core at Bcl-xL mediates its structural stability and binding affinity with BH3-domain peptide of pro-apoptotic protein.
    Feng Y; Zhang L; Hu T; Shen X; Ding J; Chen K; Jiang H; Liu D
    Arch Biochem Biophys; 2009 Apr; 484(1):46-54. PubMed ID: 19161970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput methods to detect dimerization of Bcl-2 family proteins.
    Whitfield J; Harada K; Bardelle C; Staddon JM
    Anal Biochem; 2003 Nov; 322(2):170-8. PubMed ID: 14596824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
    Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
    J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL.
    Orzáez M; Mondragón L; García-Jareño A; Mosulén S; Pineda-Lucena A; Pérez-Payá E
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1592-5. PubMed ID: 19237284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands.
    Kvansakul M; Yang H; Fairlie WD; Czabotar PE; Fischer SF; Perugini MA; Huang DC; Colman PM
    Cell Death Differ; 2008 Oct; 15(10):1564-71. PubMed ID: 18551131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
    Doshi JM; Tian D; Xing C
    J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cell death machinery controlled by Bax and Bcl-XL is evolutionarily conserved in Ciona intestinalis.
    Takada N; Yamaguchi H; Shida K; Terajima D; Satou Y; Kasuya A; Satoh N; Satake M; Wang HG
    Apoptosis; 2005 Dec; 10(6):1211-20. PubMed ID: 16215691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of a small-molecule inhibitor of the antiapoptotic protein Bcl-xL from a DNA-encoded chemical library.
    Melkko S; Mannocci L; Dumelin CE; Villa A; Sommavilla R; Zhang Y; Grütter MG; Keller N; Jermutus L; Jackson RH; Scheuermann J; Neri D
    ChemMedChem; 2010 Apr; 5(4):584-90. PubMed ID: 20229565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
    Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD
    J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation therapy induced changes in apoptosis and its major regulatory proteins, Bcl-2, Bcl-XL, and Bax, in locally advanced invasive squamous cell carcinoma of the cervix.
    Adhya AK; Srinivasan R; Patel FD
    Int J Gynecol Pathol; 2006 Jul; 25(3):281-7. PubMed ID: 16810067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust lanthanide-based assays for the detection of anti-apoptotic Bcl-2-family protein antagonists.
    Rega MF; Reed JC; Pellecchia M
    Bioorg Chem; 2007 Apr; 35(2):113-20. PubMed ID: 16996562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of antiapoptotic MCL-1 function by gossypol: mechanistic insights from in vitro reconstituted systems.
    Etxebarria A; Landeta O; Antonsson B; Basañez G
    Biochem Pharmacol; 2008 Dec; 76(11):1563-76. PubMed ID: 18762177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain.
    Hossini AM; Geilen CC; Fecker LF; Daniel PT; Eberle J
    Oncogene; 2006 Apr; 25(15):2160-9. PubMed ID: 16288206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bax and Bid, two proapoptotic Bcl-2 family members, inhibit homologous recombination, independently of apoptosis regulation.
    Dumay A; Laulier C; Bertrand P; Saintigny Y; Lebrun F; Vayssière JL; Lopez BS
    Oncogene; 2006 May; 25(22):3196-205. PubMed ID: 16407825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-based deconstruction of Bcl-xL inhibitors.
    Barelier S; Pons J; Marcillat O; Lancelin JM; Krimm I
    J Med Chem; 2010 Mar; 53(6):2577-88. PubMed ID: 20192224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.